Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01991457 · ClinicalTrials.gov registry record · Phase 2
Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01991457 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 19 participants.
The verdict
NCT01991457, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this research is to test if the conditioning regimen, fludarabine and total body irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment regimen for ALL patients older than 40 years of age and/or younger patients with high risk medical conditions. The primary objective is to establish the efficacy of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen. The investigators are also assessing the safety and toxicity of allo HCT in older ALL patients using myeloablative FluTBI conditioning regimen.
Interventions
- DRUG Fludarabine
- PROCEDURE Total Body Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-08-27 |
| Est. Completion | 2022-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01991457
The ClinicalTrials.gov registry entry for NCT01991457 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fludarabine is the first listed.
NCT01991457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01991457 about?
NCT01991457 is a clinical study titled "Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia". The goal of this research is to test if the conditioning regimen, fludarabine and total body irradiation (FluTBI), can lead to a safer and more effective stem cell transplant treatment regimen for ALL patients older than 40 years of age and/or younger patients with high risk medical conditions. The ...
What is the current status of trial NCT01991457?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2013-08-27. Estimated completion is 2022-08-23.
What interventions are being tested in trial NCT01991457?
The interventions under investigation include: Fludarabine (DRUG), Total Body Irradiation (PROCEDURE).
Who is sponsoring clinical trial NCT01991457?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.